TWST — Twist Bioscience Corporation
Is TWST overbought or oversold? Here is the current MarketMoodz read.
Twist Bioscience Corporation (TWST) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $112.00. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$112.00
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
Twist Bioscience benefits from durable end-market demand for synthetic DNA and an increasingly recurring revenue mix from consumables and services. Ongoing investments in automation and capacity should support margin expansion and higher throughput, while strategic partnerships with pharma/biotech provide commercialization proof points and multi-year revenue opportunities. Near-term upside is supported by constructive market flows into select growth and biopharma service names, but the company remains exposed to competitive pricing, execution on scale, capital/dilution risk, and regulatory/biosecurity considerations. Monitor quarterly results for revenue cadence, gross margin progress, customer diversification metrics, and any capital raises or material operational updates.
Key factors
- Strong secular demand for synthetic DNA from biopharma, genomics, and industrial synthetic biology applications supporting revenue growth
- Recurring consumables and service revenue model (oligos, libraries, platform services) that increases revenue visibility as throughput scales
- Investments in automation and capacity expansion should drive per-unit cost declines and margin improvement over time
- Strategic collaborations and commercial partnerships with large pharma/biotech customers that validate platform and create multi-year pull-through
- Favorable macro market tone for selective growth names and sector rotation into specialty biopharma services creating near-term investor interest
- Limited social/research noise in the short term reduces catalyst-driven volatility from social sentiment
Risks
- Intense competition from incumbent and emerging DNA synthesis vendors leading to pricing pressure and margin compression
- Execution risk on capacity expansion, automation rollouts and quality control as volume scales
- Capital intensity and potential dilution risk if additional financing is required to fund growth initiatives
- Customer concentration risk if a small number of large partners account for a meaningful share of revenue
- Supply‑chain disruptions or shortages of critical components could impede production throughput
- Regulatory, biosecurity or export-control developments increasing compliance costs or restricting certain customers/applications
- Broader market volatility or a shift away from growth/biotech exposures could compress multiples despite underlying growth
See today's live rating, score and targets
Members see the live hourly rating for TWST — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.